Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-Center Phase 2 Clinical Trial to Evaluate Efficacy and Safety of EC-18 in Moderate to Severe Atopic Dermatitis

NCT06487000 is registered in ClinicalTrials.gov with Enzychem Lifesciences Corporation as lead sponsor.

NCT NCT06487000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06487000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-Center Phase 2 Clinical Trial to Evaluate Efficacy and Safety of EC-18 in Moderate to Severe Atopic Dermatitis
Lead sponsor
Enzychem Lifesciences Corporation
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 31, 2027
Completion date
December 31, 2027
Enrollment
150 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis